Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept
Authors' conclusion
Among individual patients with polyarticular-course JIA treated with abatacept who achieved 1 of the combined clinical and patient-reported outcomes composite end points, many maintained them over 21 months of abatacept treatment.
Study context
- Population
- Patients with polyarticular-course juvenile idiopathic arthritis (JIA) treated with abatacept (subcutaneous and intravenous trials)219 SC abatacept
- Primary endpoint
- Maintenance of month 13 and 21 composite end points (LDA+pain-min, LDA+C-HAQ DI0, ACR50+pain-min) in those who achieved them at month 4
- Follow-up
- Months 13 and 21
Methodological detailssubcutaneous abatacept trial and intravenous abatacept trial data
- Subcutaneous abatacept trial and intravenous abatacept trial data
Primary result
As reported in the abstract
Maintenance of LDA+pain-min among month-4 achievers
Maintained low disease activity (LDA)+pain-min at month 13
84.7%
83 of 98
Maintained LDA+pain-min at month 21
65.3%
64 of 98
Further findings
Composite end points achieved at month 4
- LDA+pain-min
- 44.7%
- LDA+C-HAQ DI0
- 19.6%
- ACR50+pain-min
- 58.9%
Proportion meeting LDA+pain-min · month 4 to month 21
- Month 4
- 44.7% (98 of 219)
- Month 21
- 54.8% (120 of 219)
Proportion meeting LDA+C-HAQ DI score of 0 · month 4 to month 21
- Month 4
- 19.6% (43 of 219)
- Month 21
- 28.8% (63 of 219)
Original publication
Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care Res (Hoboken). Published 22 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →